Crescent Capital BDC (CCAP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CCAP SEC filings page.
Crescent Capital BDC, Inc. (CCAP) reported $156.4M in revenue over the twelve months to Jun 30, 2026, down 14.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The reported figures describe an investment vehicle with a stable asset base, volatile earnings, and cash flow that did not move in lockstep.
From FY2024 to FY2025, net income fell53.1% while operating cash flow rose26.8% ; that divergence means reported earnings were more volatile than cash generation, rather than reflecting a comparable contraction in cash activity.
Assets slipped
Long-term debt fell
Financial Health Signals
Crescent Capital BDC, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Crescent Capital BDC, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
For every $1 of reported earnings, Crescent Capital BDC, Inc. generates $2.17 in operating cash flow ($74.7M OCF vs $34.5M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Crescent Capital BDC, Inc. reported an operating loss of $98.7M against $57.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Crescent Capital BDC, Inc. generated $36.3M in revenue in Q2 2026. This represents a decrease of 15.5% from the same quarter a year earlier. Against the prior quarter it is down 4.2%.
Crescent Capital BDC, Inc. reported a net loss of $3.2M in Q2 2026. This represents a decrease of 121.6% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Crescent Capital BDC, Inc. held $15.6M in cash against $922.9M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Crescent Capital BDC, Inc.'s operating margin was -62.5% in Q2 2026, reflecting core business profitability. This is down 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.9 percentage points.
Crescent Capital BDC, Inc.'s net profit margin was -8.9% in Q2 2026, showing the share of revenue converted to profit. This is down 43.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 32.0 percentage points.
Crescent Capital BDC, Inc.'s quarterly ROE was -0.5% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.
Not reported for Q2 2026.
Capital Allocation
Crescent Capital BDC, Inc. spent $667K on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is down 33.3%.
Not reported for Q2 2026.
Not reported for Q2 2026.
CCAP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.3M-15.5% | $37.9M-10.0% | $40.8M-12.1% | $41.4M-19.9% | $43.0M-12.2% | $42.1M-16.3% | $46.4M-7.1% | $51.6M+7.2% |
| Operating Income | -$22.7Mn/m | -$21.9Mn/m | -$23.8Mn/m | -$24.1Mn/m | -$25.7Mn/m | -$25.0Mn/m | -$25.8Mn/m | -$27.4Mn/m |
| Interest Expense | $14.9M-1.9% | $13.7M-6.1% | $13.8M-8.9% | $13.9M-13.8% | $15.2M-4.9% | $14.6M-6.2% | $15.1M-3.8% | $16.1M+4.7% |
| Income Tax | $25Kn/m | N/A | $0n/m | $0-100.0% | $0n/m | $6K | $0 | $155K |
| Net Income | -$3.2M-121.6% | -$15.5M-497.4% | $8.5M-15.0% | $7.1M-53.5% | $15.0M-26.4% | $3.9M-86.1% | $10.0M-67.6% | $15.3M-32.5% |
| EPS (Basic) | N/A | $0.42-6.7% | $0.45-18.2% | $0.46 | $0.46-22.0% | $0.45 | $0.55 | $0.64 |
| EPS (Diluted) | N/A | $0.42-6.7% | $0.45-18.2% | $0.46 | $0.46-22.0% | $0.45 | $0.55 | $0.64 |
| Diluted Shares (Avg) | 37M-0.6% | 37M-0.4% | N/A | 37M | 37M0.0% | 37M | N/A | 37M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, EBITDA.
CCAP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6B-2.1% | $1.6B-2.9% | $1.6B-2.1% | $1.6B-1.1% | $1.7B-1.1% | $1.7B+2.8% | $1.7B+1.8% | $1.6B+1.3% |
| Cash & Equivalents | $15.6M+60.2% | $6.1M-49.0% | $5.0M-50.2% | $5.8M-66.1% | $9.7M-11.6% | $12.0M+78.5% | $10.1M+30.2% | $17.1M+184.8% |
| Total Liabilities | $962.4M+3.5% | $943.6M+0.5% | $916.1M+0.1% | $913.6M+1.9% | $929.7M+1.1% | $939.4M+8.1% | $915.6M+3.5% | $896.2M+0.2% |
| Long-Term Debt | $922.9M+4.0% | $907.1M+0.5% | $873.8M-0.2% | $875.3M+2.1% | $887.3M+0.8% | $903.0M+8.6% | $875.8M+3.7% | $857.2M+0.1% |
| Total Equity | $656.5M-9.4% | $674.0M-7.3% | $706.0M-4.7% | $714.1M-4.6% | $724.7M-3.7% | $727.1M-3.3% | $740.6M-0.3% | $748.8M+2.5% |
| Retained Earnings | -$298.9Mn/m | -$282.0Mn/m | -$251.0Mn/m | -$244.7Mn/m | -$234.4Mn/m | -$232.0Mn/m | -$218.5Mn/m | -$217.1Mn/m |
Not reported in any period shown, so not listed: Current Assets, Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Current Liabilities, Non-Current Liabilities.
CCAP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $9.8M-73.0% | -$23.8Mn/m | $22.6Mn/m | $30.8M-34.4% | $36.4Mn/m | -$15.1M-138.3% | -$2.9M-108.3% | $46.9M+119.8% |
| Financing Cash Flow | -$613Kn/m | $18.8M+195.6% | -$18.9M-480.6% | -$29.1Mn/m | -$40.9M-242.2% | $6.3Mn/m | $5.0Mn/m | -$45.3Mn/m |
| Dividends Paid | $16.6M-4.5% | $15.5M-10.9% | $15.6M-14.3% | $17.4M-7.9% | $17.4M-9.6% | $17.4M-7.8% | $18.2M-2.0% | $18.9M+4.1% |
| Share Buybacks | $667K | $1.0M | $1.0M | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow.
CCAP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -62.5%-2.8pp | -57.7%+1.7pp | -58.4%-2.7pp | -58.4%-5.2pp | -59.8%-5.0pp | -59.4%-6.4pp | -55.7%-2.1pp | -53.1%+1.0pp |
| Net Margin | -8.9%-43.9pp | -40.9%-50.2pp | 20.8%-0.7pp | 17.2%-12.4pp | 34.9%-6.7pp | 9.3%-46.3pp | 21.5%-40.3pp | 29.6%-17.4pp |
| Return on Equity | -0.5%-2.6pp | -2.3%-2.8pp | 1.2%-0.1pp | 1.0%-1.1pp | 2.1%-0.6pp | 0.5%-3.2pp | 1.4%-2.8pp | 2.0%-1.1pp |
| Return on Assets | -0.2%-1.1pp | -1.0%-1.2pp | 0.5%-0.1pp | 0.4%-0.5pp | 0.9%-0.3pp | 0.2%-1.5pp | 0.6%-1.3pp | 0.9%-0.5pp |
| Debt-to-Equity | 1.41+0.2x | 1.35+0.1x | 1.24+0.1x | 1.23+0.1x | 1.22+0.1x | 1.24+0.1x | 1.180.0x | 1.140.0x |
| Liabilities-to-Equity | 1.47+0.2x | 1.40+0.1x | 1.30+0.1x | 1.28+0.1x | 1.28+0.1x | 1.29+0.1x | 1.240.0x | 1.200.0x |
| Asset Turnover | 0.020.0x | 0.020.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.030.0x |
Not reported in any period shown, so not listed: Gross Margin, Current Ratio, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Crescent Capital BDC, Inc. CCAP | FY2025 | $167.3M | $34.5M | 20.6% | $341.6M | — |
| BlackRock TCP Capital Corp. TCPC | FY2025 | N/A | -$88.9M | N/A | $350.7M | — |
| CION Investment Corporation CION | FY2025 | $240.8M | -$20.6M | -8.6% | $343.9M | 30/100 |
| Palmer Square Capital BDC Inc. PSBD | FY2025 | $124.4M | -$3.2M | -2.5% | $304.4M | 43/100 |
Where Crescent Capital BDC, Inc. Ranks
Frequently Asked Questions
Crescent Capital BDC, Inc. (CCAP) reported $167.3M in total revenue for fiscal year 2025. This represents a -15.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Crescent Capital BDC, Inc. (CCAP) revenue declined by 15.2% year-over-year, from $197.4M to $167.3M in fiscal year 2025.
No, Crescent Capital BDC, Inc. (CCAP) reported a net loss of $3.2M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $34.5M, with a net profit margin of 20.6%.
As of fiscal year 2025, Crescent Capital BDC, Inc. (CCAP) had $5.0M in cash and equivalents against $873.8M in long-term debt.
Crescent Capital BDC, Inc. (CCAP) had an operating margin of -59.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Crescent Capital BDC, Inc. (CCAP) had a net profit margin of 20.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Crescent Capital BDC, Inc. (CCAP) has a return on equity of 4.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Crescent Capital BDC, Inc. (CCAP) generated $74.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Crescent Capital BDC, Inc. (CCAP) had $1.6B in total assets as of fiscal year 2025, including both current and long-term assets.
Crescent Capital BDC, Inc. (CCAP) had a debt-to-equity ratio of 1.24 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Crescent Capital BDC, Inc. (CCAP) had a liabilities-to-equity ratio of 1.30 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Crescent Capital BDC, Inc. (CCAP) had a return on assets of 2.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Crescent Capital BDC, Inc. (CCAP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $341.6M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Crescent Capital BDC, Inc. (CCAP) trades at 2.2x sales, its market capitalization divided by $156.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $341.6M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Crescent Capital BDC, Inc. (CCAP) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Crescent Capital BDC, Inc. (CCAP) has an earnings quality ratio of 2.17x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Crescent Capital BDC, Inc. (CCAP) reported an operating loss of $98.7M against $57.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.